Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GPRC5D CAR-T in r/r Multiple Myeloma
NCT05749133Phase 2Recruiting
- Sponsor
- Xuyan Biotechnology
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-GPRC5D CAR-T in multiple myeloma (MM), sponsored by Xuyan Biotechnology. Started Apr 2023; status: recruiting.
02
Drugs
anti-GPRC5D CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05749133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749133.